Patients 50 Years and Older Satisfied with ACL Reconstruction

Why It Matters

The data overturn long‑standing age bias, indicating that older adults can safely regain knee function, influencing orthopedic practice and patient counseling. This could expand the market for ACL procedures and improve quality of life for a growing senior demographic.

Key Takeaways

• 91.5% patients satisfied with ACL reconstruction
• Graft failure occurred in 7.1% of cases
• 63.8% returned to prior activity level
• 82% had concomitant meniscal lesions
• Bone‑tendon‑bone allograft used in 56.8% surgeries

Pulse Analysis

The anterior cruciate ligament (ACL) has long been considered a youth‑centric injury, with surgeons often hesitant to operate on patients in their 50s and beyond. Recent data presented at the American Academy of Orthopaedic Surgeons (AAOS) meeting challenges that bias, showing that older adults can achieve outcomes comparable to younger cohorts when the procedure is appropriately indicated. Advances in graft technology, refined rehabilitation protocols, and a growing emphasis on functional longevity have collectively broadened the therapeutic window for ACL reconstruction.

The NYU Langone Health retrospective analysis examined 155 patients aged 50 and older who underwent primary ACL reconstruction between 2011 and 2023. With a minimum two‑year follow‑up, 91.5 % reported that the surgery met their expectations and 83.9 % rated satisfaction as good or excellent. Objective scores reflected solid results—mean IKDC of 78.1 and a 1.8‑point rise in Tegner activity. Graft failure was limited to 7.1 %, while 63.8 % returned to their pre‑injury activity level, despite 82 % presenting concomitant meniscal pathology.

These findings carry practical implications for orthopedic decision‑making. Surgeons can counsel eligible patients over 50 that ACL reconstruction offers a high likelihood of functional restoration without markedly increasing the risk of conversion to total knee arthroplasty. The predominance of bone‑tendon‑bone allografts (56.8 %) suggests a preference for tissue that balances durability with reduced donor‑site morbidity in an older population. Nonetheless, the study’s retrospective design underscores the need for prospective, randomized trials to validate durability, cost‑effectiveness, and long‑term quality‑of‑life benefits.